Study Comparing On-Demand Treatment With Two Prophylaxis Regimens Of BeneFIX In Patients With Severe Hemophilia B

Hemophilia B Clinical Trial

Official title:

A Multicenter, Open-Label Study To Compare On-Demand Treatment With 2 Prophylaxis Regimens of Recombinant Coagulation Factor IX (BeneFIX) Reformulated Drug Product (rFIX-R) In Subjects With Severe Hemophilia B

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00364182
• Other study ID #: 3090A1-400
• Secondary ID: B1821002
• Status: Completed
• Phase: Phase 3
• First received: August 14, 2006
• Last updated: August 30, 2011
• Start date: May 2007
• Est. completion date: October 2010

Study information

• Verified date: August 2011
• Source: Pfizer
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This study is designed to evaluate BeneFIX infused as prophylaxis regimens, compared with BeneFIX administered as an on-demand regimen only. In the trial, subjects will participate in 4 study periods. The first period is a 16-week on-demand treatment, during which subjects will utilize BeneFIX to treat bleeding events episodically only as they occur (i.e., on-demand treatment). At the end of this period, subjects will be randomly assigned to 1 of 2 BeneFIX prophylaxis regimens: either 100 IU/kg once weekly or 50 IU/kg twice weekly, and followed for 16 weeks. At the end of this period, subjects will use on-demand treatment for 8 weeks. The purpose of this 8-week period is to mitigate the potential carry-over effect of the prior prophylaxis regimen on bleeding frequency. Following this 8-week on-demand treatment, subjects will cross-over and receive the alternate study prophylactic regimen for 16 weeks.

The primary endpoint is annualized number of bleeding episodes, compared between the first on-demand period and each of the prophylaxis regimens. A comparison of annualized bleeding episodes between the two prophylaxis regimens will also be performed. Subject-reported outcomes will also be collected using a patient diary. At 24 and 48 hours following the onset of each joint bleeding episode, information on pain, sleep, and work will be collected. Additional data on physical functioning will be recorded on the diary at the end of the 16-week on-demand period, and at the end of each prophylaxis period. Information on safety will also be collected.

Each subject will participate in this study for approximately 59 weeks (15 months), including a screening period of up to 3 weeks, an initial 16-week on-demand period, two prophylaxis treatment periods of 16 weeks each, separated by an 8-week on-demand treatment period.

A modified FIX recovery study will be performed once during each prophylaxis period.

The study diary will also be used by subjects to collect secondary endpoints. These endpoints, which are subject-reported outcomes, will be recorded in the diary at 24 and 48 hours following the onset of each joint bleeding episode. Additional data on physical functioning will be recorded on the diary at the end of the 16-week on-demand period, and at the end of each prophylaxis period.

Patients will be recruited in the United States, Canada, Europe and Russia.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 50
• Est. completion date: October 2010
• Est. primary completion date: October 2010
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 6 Years to 65 Years

Eligibility

Inclusion Criteria:

• Documented history of moderately severe or severe hemophilia B (FIX:C less than or equal to 2%)

• Male subjects, aged 6 years to 65 years.

• Subjects with a minimum of 12 bleeding episodes, 6 of which must be joint bleeds, in the 12 months before screening.

Exclusion Criteria:

• Subjects currently utilizing FIX primary prophylaxis.

• Subjects with HIV+ who have a CD4 count less than 200

• Subjects with hepatic or renal impairment.

• Prothrombin time or International Normalized Ration more than 1.5 times the upper limit of normal.

• Major surgery or an orthopedic surgical procedure within the past 3 months or is planned within the duration of participation in this study.

• Past history of, or current FIX inhibitor.

• Hypersensitivity to any FIX product or hamster protein.

• Exposure to any investigational drug, except for rFIX-R, or device within 30 days of providing consent/assent (as appropriate) for this study.

• Bleeding disorders other than hemophilia B.

• Concurrent inflammatory disease that in the investigator's judgment could confound the study results.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

• Hemophilia A
• Hemophilia B

Intervention

Drug:
• Recombinant Coagulation Factor IX (BeneFIX)
100 IU/kg once weekly then crossover to 50 IU/kg twice weekly
• Recombinant Coagulation Factor IX (BeneFIX)
50 IU/kg twice weekly then crossover to 100 IU/kg once weekly

Locations

Country	Name	City	State
Canada	Pfizer Investigational Site	Edmonton	Alberta
Canada	Pfizer Investigational Site	Edmonton	Alberta
Canada	Pfizer Investigational Site	Ottawa	Ontario
Croatia	Pfizer Investigational Site	Zagreb
Hungary	Pfizer Investigational Site	Budapest
Italy	Pfizer Investigational Site	Castelfranco Veneto (TV)
Italy	Pfizer Investigational Site	Coppito (AQ)
Romania	Pfizer Investigational Site	Bucuresti
Russian Federation	Pfizer Investigational Site	Moscow
Russian Federation	Pfizer Investigational Site	Saint Petersburg
Serbia	Pfizer Investigational Site	Belgrade
Serbia	Pfizer Investigational Site	Nis
Spain	Pfizer Investigational Site	Madrid
Spain	Pfizer Investigational Site	Sevilla
United States	Pfizer Investigational Site	Chicago	Illinois
United States	Pfizer Investigational Site	Chicago	Illinois
United States	Pfizer Investigational Site	Houston	Texas
United States	Pfizer Investigational Site	New Brunswick	New Jersey
United States	Pfizer Investigational Site	Phoenix	Arizona

Sponsors (1)

Lead Sponsor	Collaborator
Pfizer

Countries where clinical trial is conducted

United States,  Canada,  Croatia,  Hungary,  Italy,  Romania,  Russian Federation,  Serbia,  Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Annualized Number of Bleeding Episodes	Annualized bleed rate (ABR) or number of bleeds per year derived for each participant for each treatment regimen by using the following formula: ABR = number of bleeds / (days on treatment regimen / 365.25)	Baseline up to Week 56	No
Secondary	Amount of Sleep Measured by Sleep Diary After Hemarthrosis	For each bleeding event, a diary was filled out that night and the subsequent night. Questions included: How long do you think you slept last night? Reported as average duration of sleep during study.	24 and 48 hours post-bleed	No
Secondary	Quality of Sleep Measured by Sleep Diary After Hemarthrosis	For each bleeding event, a diary was filled out that night and the subsequent night. Questions included: How would you describe the quality of your sleep last night? 1=Very Good, 2=Good, 3=Fair, 4=Poor, 5=Very Poor. Reported as quality of sleep during study.	24 and 48 hours post-bleed	No
Secondary	Acute Pain After Hemarthrosis	For each bleeding event, a diary was filled out that night and the subsequent night and included a Brief Pain Inventory (BPI): self-reported scale that measured severity of pain experienced over the past 24 hours. Questions included How much pain right now? 0 (no pain) to 10 (pain as severe as you can imagine).	24 and 48 hours post-bleed	No
Secondary	Health-Related Productivity Questionnaire (HRPQ) Score: Hours Lost From Work or School at 24 Hours Post-bleed	HRPQ: self-reported scale that measured for each bleed event, hours lost from work, school and housework because of hemophilia and its treatments. Mean and standard deviations calculated from measured values.	24 hours post-bleed	No
Secondary	HRPQ Score: Hours Lost From Work or School at 48 Hours Post-bleed	HRPQ: self-reported scale that measured for each bleed event, hours lost from work, school and housework because of hemophilia and its treatments. Mean and standard deviations calculated from measured values.	48 hours post-bleed	No
Secondary	36-Item Short-Form Health Survey (SF-36): Physical Functioning Domain	SF-36: standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, and mental health. The physical functioning domain score was an average of the individual physical functioning question scores across all time points, which was scaled 0-100 (100=highest level of functioning).	Weeks 16, 32, and 56	No

External Links

•   To obtain contact information for a study center near you, click here.